BRAINERD MARY K purchased $27K of SYK (indirect holdings)

BRAINERD MARY K purchased 131 indirectly-held shares of STRYKER CORP (SYK) at an average of $204.09 ($185.65–$225.20) across 5 trades over 2019-06-26 to 2022-11-22.

Original reporting
SEC EDGAR · BRAINERD MARY K
Published Sep 2, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
high confidence
Mentioned
$SYK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

The disclosed purchase is unlikely to influence Stryker's share price or investor sentiment.

02

Market read

Low relevance; a routine insider purchase with minimal market impact.

03

What to watch

Potential future insider activity or upcoming board decisions could become relevant, but not evident now.

Relevance 4/10Novelty 4/10Timing: filed 2026-09-02

Background

Form 4 filings disclose insider transactions; this filing reports a director's modest purchase of Stryker shares.

Company-level read

Ticker impact

$SYKNeutralHigh confidence
Context

Director Mary K. Brainder purchased 131 shares of Stryker totaling $27K via open-market trades.

Expected impact

minimal to none

Evidence & confidence

Insider buying under $30K by a director is a routine disclosure with negligible market effect.

Market effects

None; the transaction does not affect the broader medical device sector.

None; limited to a single insider trade.

None; no global market implications.

Counterpoint

Even small insider purchases can signal confidence, but the amount is too trivial to act on.

Key entities

  • Stryker Corp.

    Medical device manufacturer (ticker SYK).

  • Mary K. Brainder

    Director of Stryker who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

$SYKHighAI 8/10

Stifel cuts Stryker stock price target on weak quarter, guidance

Stifel reduced its price target for Stryker (NYSE:SYK) to $325 from $330, maintaining a Buy rating after the company's Q3 results missed expectations. Stryker reported Q3 sales of $6.52B, below estimates, and lowered its full-year organic sales growth guidance to 6.5-7.0%. Multiple analysts have revised earnings downward, citing execution issues and market slowdowns.

$SYKHighAI 8/10

Stryker Earnings Call Balances Growth With Caution

Stryker Corp (SYK) reported Q3 earnings with 7.7% organic sales growth, 10.3% adjusted EPS increase to $3.52, and margin expansion. Growth was led by MedSurg and Neurotechnology, while Orthopaedics faced challenges. Management highlighted strong capital demand, innovation pipeline, and M&A activity, but acknowledged hip and knee market slowdowns and execution issues.